
A study of 1,334 men diagnosed with non-metastatic prostate cancer showed a significantly increased risk of recurrence in those who consumed more than four servings of whole milk per week.
The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.
A study of 1,334 men diagnosed with non-metastatic prostate cancer showed a significantly increased risk of recurrence in those who consumed more than four servings of whole milk per week.
The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.
The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.
Data from a pilot study showed an added benefit from the incorporation of extra virgin olive oil into the diets of men with low-risk prostate cancer. As a result, this dietary modification could lead to weight loss, while also helping the body to absorb compounds with anticancer properties.